Hematology

Latest News

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com

AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

By Kimberly Rath, PharmD

August 14th 2025

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com

QRISK3 Tool Predicts Thrombotic Events in ET, PV

By Jared Kaltwasser

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com

New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

By Jared Kaltwasser

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com

Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

By Maggie L. Shaw

July 31st 2025

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com

Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

By AJMC Contributor

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez

Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.

October 20th 2017

Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia

CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.

October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina

Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.

October 16th 2017

St. Jude Study Questions Efficacy of the Flu Vaccine in Children With Leukemia

Surabhi Dangi-Garimella, PhD

The study found that young patients with leukemia who have been vaccinated against the influenza virus are as susceptible to develop flu as their unvaccinated peers.

October 16th 2017

Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer

Brandon R. Shank, PharmD, MPH, BCOP Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS Emily C. Pherson, PharmD, BCPS

With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.

October 13th 2017

Study: Body Fat Composition May Predict Poor Treatment Outcomes in Patients With Multiple Myeloma

A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma.

October 13th 2017

In Conversation With a Pharmacist: Management of CAR T-Cell Treatment

Surabhi Dangi-Garimella, PhD

Evidence-Based OncologyTM sat down with Brandon R. Shank, PharmD, MPH, BCOP, clinical pharmacy specialist, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, to understand a pharmacist's role in administering chimeric antigen receptor (CAR) T cells.

October 12th 2017

Second Interim Analysis Suggests Carfilzomib Improves Survival in Multiple Myeloma

Alison Rodriguez

Following the phase 3 ENDEAVOR trial that compared 2 proteasome inhibitors-carfilzomib and bortezomib-in relapsed or refractory multiple myeloma patients, researchers conducted a second interim analysis to compare the overall survival between the 2 groups.

October 10th 2017

Study Finds Antibiotic Effective in Reducing Rate of Infection in Children With ALL

Alison Rodriguez

October 7th 2017

LLS Survey Shows Lack of Blood Cancer Awareness in the United States

Alison Rodriguez

A recent survey by The Leukemia & Lymphoma Society found that the majority of adults are surprised by the prevalence of blood cancers-specifically the prevalence of acute lymphocytic leukemia among children and young adults.

October 6th 2017

Report Analyzes Pipeline of Drugs for Treating Chemotherapy-Related Toxicities

Alison Rodriguez

A recent report, “Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017,” presents a summary of drugs in development to treat chemotherapy-related toxicities.

September 18th 2017

New CDC Report Provides Update on Incidence Rates of Pediatric ALL

Surabhi Dangi-Garimella, PhD

New results published in CDC’s Morbidity and Mortality Weekly Report have identified a surge in pediatric acute lymphoblastic leukemia (ALL) during the period 2001 to 2008, followed by stabilization during 2008 to 2014.

September 15th 2017

Copanlisib Receives Accelerated Approval for Relapsed Follicular Lymphoma

Christina Mattina

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

September 1st 2017

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

August 25th 2017

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

August 24th 2017

Study Finds HPV Vaccination Underutilized by Childhood Cancer Survivors

Surabhi Dangi-Garimella, PhD

A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.

August 21st 2017

FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia

Alison Rodriguez

The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

August 14th 2017

Matching PROs With Medical Records to Assess Comorbidities in Prostate Cancer

Surabhi Dangi-Garimella, PhD

Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.

August 9th 2017

Results of Phase 2 Study Investigating Luspatercept in MDS

Alison Rodriguez

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.

August 4th 2017

5 Developments With Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

August 1st 2017

Enasidenib Approved for IDH2-Mutated Patients With Relapsed/Refractory AML

Surabhi Dangi-Garimella, PhD

Enasidenib (Idhifa), developed by Celgene and Agios, has been granted FDA approval in tandem with a companion diagnostic test to detect IDH-2 mutations.

July 28th 2017

Breakthrough Therapy Designation for Venetoclax in AML

Venetoclax (Venclexta), in combination with low dose cytarabine, has been granted a breakthrough therapy designation for use in elderly, treatment-naive patients with acute myeloid leukemia (AML) who cannot handle intensive chemotherapy.

July 24th 2017

Kite's CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds

Christina Mattina

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

July 17th 2017

Daratumumab-Based Combination Effective in Relapsed/Refractory Multiple Myeloma, Short PFS in Heavily Pretreated Patients

Surabhi Dangi-Garimella, PhD

Managing heavily pretreated, often less fit, patients with relapsed/refractory multiple myeloma is a challenge in routine practice, as illustrated by the fact progression-free survival remains short, although daratumumab-based combination therapies are proven effective, according to results presented during a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

July 17th 2017

Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.

July 17th 2017

Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Updated trial results at the 2017 Annual Meeting of the American Society of Clinical Oncology showed the combinations of daratumumab with either lenalidomide and dexamethasone or bortezomib and dexamethasone prolonged progression-free survival for patients with relapsed refractory multiple myeloma.

July 12th 2017

CHESS Study Investigates Economic Burden of Severe Hemophilia in Europe

Alison Rodriguez

Severe hemophilia often results in a significant economic and psychological burden on patients, caregivers, and the healthcare system as a whole, according to recent research from Europe.

...

22 23 24 25 26 27 28 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions